Michael Simon, MD
Internal Medicine · Sayreville, NJNPI 1538185657
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by AstraZeneca at 29.6% of the total. 2025 is the largest year on record at $17,677, 4.4 times the $4,016 reported in 2019. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,032 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Sanofi-aventis U.S. LLC$12K
- AbbVie$3K
- Novo Nordisk$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $16K from 47 others
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$20,75240%
- Travel & lodging$1,2322%
- Food & beverage$29,04056%
- Education$510%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,276 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 93 | $126,306 |
| OzempicSemaglutide | 92 | $118,309 |
| EliquisApixaban | 160 | $102,351 |
| JardianceEmpagliflozin | 42 | $56,447 |
| OtezlaApremilast | 16 | $50,229 |
| JanuviaSitagliptin Phosphate | 21 | $31,009 |
| RybelsusSemaglutide | 19 | $29,738 |
| CyclosetBromocriptine Mesylate | 18 | $24,103 |
| KerendiaFinerenone | 25 | $23,809 |
| XareltoRivaroxaban | 15 | $21,457 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $20,285 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $17,572 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $16,239 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,318 |
| Icosapent Ethyl | 30 | $14,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,756 | $148,047111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $15,475 | $141,624111 claims |
| PfizerEliquis | $698 | $102,351160 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $779 | $71,60767 claims |
| AmgenOtezla, Corlanor | $1,066 | $57,28134 claims |
| MerckJanuvia, Janumet | $858 | $51,29335 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $1,170 | $25,44033 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $1,696 | $24,10318 claims |
| BayerKerendia | $1,078 | $23,80925 claims |
| Johnson & JohnsonXarelto | $1,211 | $21,45715 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11,897 | $16,23921 claims |
| Esperion Therapeutics, Inc.Nexlizet | $160 | $8,04722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Sayreville
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.